Merck & Co., Inc. (MRK) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024. Merck & Co., Inc. operates through two primary segments: Pharmaceutical (human health) and Animal Health. The quarter was characterized by strong oncology sales growth, significant business development activity including multiple asset acquisitions, and a strategic restructuring program aimed at optimizing global manufacturing networks.
Key Financial Metrics
| Metric ($ in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Sales | $16,657 | $15,962 | $48,544 | $45,485 |
| Net Income (Attributable to Merck) | $3,157 | $4,745 | $13,374 | $1,591 |
| Diluted EPS | $1.24 | $1.86 | $5.26 | $0.62 |
| Operating Cash Flow (9M) | $18,018 (2024) vs $12,760 (2023) | |||
| Free Cash Flow (9M) | $15,583 (2024) vs $9,886 (2023) | |||
| Total Debt | $38,131 (Sep 30, 2024) vs $35,055 (Dec 31, 2023) | |||
| Cash & Investments | $15,168 (Sep 30, 2024) vs $7,345 (Dec 31, 2023) | |||
| Gross Margin | 75.5% | 73.3% | 76.6% | 73.1% |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 4% in Q3 and 7% in the first nine months of 2024. Excluding foreign exchange, growth was 7% (Q3) and 10% (9M). Growth was driven by the oncology franchise (Keytruda up 17% in Q3) and the launch of Winrevair.
- Profitability Decline (Q3): Net income decreased 33% in Q3 2024 compared to Q3 2023. This was primarily due to a $2.2 billion increase in R&D expenses driven by acquisition charges (EyeBio, MK-1045, Harpoon) and a $100 million milestone payment.
- Profitability Surge (9M): Net income for the first nine months increased significantly (745% YoY) due to a low base in 2023, which included a $10.2 billion charge for the Prometheus acquisition.
- Segment Performance: Pharmaceutical segment profits grew 11% in Q3. Animal Health profits grew 21% in Q3, aided by the Elanco aqua business acquisition.
- Balance Sheet: Cash and cash equivalents more than doubled to $14.6 billion, supported by strong operating cash flows and a €3.4 billion Euro note issuance in May 2024.
Guidance, Outlook, and Risks
- Business Development: Merck recorded significant R&D charges in Q3 for the acquisitions of EyeBio ($1.35 billion charge), MK-1045 ($750 million charge), and Harpoon ($656 million charge). These are accounted for as asset acquisitions.
- Restructuring: A new 2024 Restructuring Program was approved with estimated cumulative costs of $4.0 billion, expected to generate $750 million in annual net cost savings by 2031. $279 million in costs were recorded in Q3 2024.
- Product Outlook:
- Keytruda: Continued strong growth with multiple new approvals in 2024 (cervical, gastric, biliary, mesothelioma).
- Gardasil/Gardasil 9: Sales declined 11% in Q3 due to lower demand in China; the company expects sales to decline in 2024 and 2025 compared to prior years.
- Januvia/Janumet: Sales declined 42% in Q3 due to pricing pressure, Medicaid rebate cap elimination, and generic competition in international markets.
- Lagevrio: Sales declined 40% in Q3 due to lower demand in Asia Pacific.
- Risks & Contingencies:
- Legal: Ongoing litigation regarding Dr. Scholl's foot powder (talc), Gardasil (vaccine liability), and patent disputes (Keytruda, Januvia, Bridion).
- Regulatory: The FDA issued a Complete Response Letter (CRL) for patritumab deruxtecan (MK-1022) due to manufacturing inspection findings (not efficacy/safety). Merck withdrew its application for gefapixant (chronic cough) following a second CRL.
- Tax: The company expects a $270 million tax benefit in Q4 2024 from the expiration of the statute of limitations for the 2020 federal tax return.
Investor Verification Checklist
- Acquisition Charges: Verify the impact of the $2.2 billion in Q3 R&D charges (EyeBio, MK-1045, Harpoon) on future earnings and whether these are one-time or recurring.
- China Exposure: Assess the long-term impact of the Gardasil sales decline in China and the company's strategy to mitigate this.
- Patent Cliffs: Monitor the timeline for Januvia/Janumet exclusivity loss in the U.S. (expected May/July 2026) and the impact of the Inflation Reduction Act (IRA) price negotiations.
- Restructuring Execution: Track the progress of the $4.0 billion restructuring program and the realization of the projected $750 million annual savings.
- Cash Flow Sustainability: Confirm that the strong operating cash flow ($18.0 billion in 9M) can sustain the dividend ($0.77/share), share buybacks ($2.9 billion remaining authorization), and future M&A activity.